Latest Headlines

  1. New AI Model Could Cut The Costs Of Developing Protein Drugs 2/16/2026

    Industrial yeasts are a powerhouse of protein production, used to manufacture vaccines, biopharmaceuticals, and other useful compounds.

  2. Akeso's IL-4Rα/ST2 Bispecific Antibody Cleared For Seven Phase II Studies In China Spanning Respiratory And Autoimmune Indications 2/11/2026

    Akeso, Inc. (9926.HK) is pleased to announce that the National Medical Products Administration has approved the initiation of Phase II clinical trials for AK139, a first-in-class IL-4Rα/ST2-targeting bispecific antibody, across seven indications.

  3. Precision BioSciences Receives U.S. FDA Clearance Of Investigational New Drug Application For First-In-Class PBGENE-DMD For Treatment Of Duchenne Muscular Dystrophy 2/11/2026

    Precision BioSciences, Inc., a clinical stage gene editing company utilizing its novel proprietary ARCUS platform to develop in vivo gene editing therapies for high unmet need diseases, today announced that the Company received a Study May Proceed notification from the U.S. Food and Drug Administration (FDA).

  4. Lantern Pharma To Present At The 7th Glioblastoma Drug Development Summit In Boston On February 17-19, 2026 2/10/2026

    Lantern Pharma Inc., a clinical-stage biopharmaceutical company leveraging artificial intelligence to accelerate oncology drug discovery and development, today announced that CEO and President Panna Sharma will present at the 7th Glioblastoma Drug Development Summit, February 17–19, 2026, in Boston, MA.

  5. AI-Powered R&D Acceleration: Insilico Medicine And CMS Announce Multiple Collaborations In Central Nervous System And Autoimmune Diseases 2/10/2026

    Insilico Medicine ("Insilico", 03696.HK), a clinical-stage biotechnology company driven by generative artificial intelligence (AI), China Medical System Holdings Limited ("CMS", 867.HK/8A8.SG), an open-platform innovative company linking pharmaceutical innovation and commercialization with strong product lifecycle management capability, today announced a series of AI‑empowered drug discovery collaborations across multiple projects in the fields of central nervous system and autoimmune diseases.

  6. Syngene Collaborates With Johns Hopkins University To Advance Early-Stage Drug Discovery 2/10/2026

    Syngene International, a global contract research, development, and manufacturing organization (CRDMO), today announced a strategic collaboration with Johns Hopkins University, MD, U.S., to advance early‑stage drug discovery programs and platform technologies emerging from the university’s research labs.

  7. LIGAND-AI Aims To Transform Early Drug Discovery Through Machine Learning 2/10/2026

    A global research initiative that includes researchers from the Leslie Dan Faculty of Pharmacy is undertaking a large-scale project to advance the use of artificial learning (AI) and machine learning to identify small molecules that bind to proteins – an essential first step in early drug discovery.

  8. U.S. Food And Drug Administration Accepts New Drug Application And Grants Priority Review For Takeda's Oveporexton (TAK-861) As A Potential First-In-Class Therapy For Narcolepsy Type 1 2/10/2026

    Takeda today announced that the U.S. Food and Drug Administration (FDA) accepted its New Drug Application (NDA) and granted Priority Review for oveporexton (TAK-861) for the treatment of narcolepsy type 1 (NT1).

  9. NextPoint Therapeutics Announces Clinical Entry Of NPX372, A First-In-Class B7-H7–Targeted T Cell Engager To Treat Solid Tumors 2/9/2026

    NextPoint Therapeutics, a clinical-stage biotechnology company developing a new world of precision therapeutics through its leading scientific work on the novel B7-H7 axis, today announced the clearance of an Investigational New Drug (IND) application with the U.S. Food and Drug Administration (FDA) to initiate clinical development of NPX372, a first-in-class T cell engager (TCE) for the treatment of patients with solid tumors.

  10. Iambic Announces Collaboration With Takeda To Advance AI-Driven Design Of Small Molecules 2/9/2026

    Iambic, a clinical-stage life science and technology company developing novel medicines using its AI-driven discovery and development platform, today announced a multi-year technology and discovery collaboration agreement with Takeda that will use Iambic’s industry leading AI drug discovery models to advance a select set of high-priority small molecule programs, initially in Takeda’s Oncology and Gastrointestinal and Inflammation therapeutic areas.